Projected Spending on Psychotropic Medications 2013–2020
- First Online:
- 231 Downloads
Spending on psychotropic medications has grown rapidly in recent decades. Using national data on drug expenditures, patent expirations, future drug development and expert interviews, we project that spending will grow more slowly over the period 2012–2020. The average annual increase is projected to be just 3.0 % per year, continuing the steady deceleration in recent years. The main drivers of this expected deceleration include slower development of new drugs, upcoming patent expirations which will lower prices, and payers’ growing ability to manage utilization and promote generic use. The slowdown will relieve some cost pressures on payers, particularly Medicare and Medicaid.
KeywordsPsychotropic medications Spending growth Generic drugs
- Aitken, M. L., Berndt, E. R., Bosworth, B., Cockburn, I. M., Frank, R., Kleinrock, M., & Shapiro, B. T. (2013). The regulation of prescription drug competition and market responses: Patterns in prices and sales following loss of exclusivity NBER Working Paper Series. Cambridge, MA: National Bureau of Economic ResearchGoogle Scholar
- Center for Medicare and Medicaid Services (2013). National health expenditure (NHE) Amounts by type of expenditure and source of funds: Calendar years 1965–2022. Retrieved May 26, 2015, from http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NationalHealthAccountsProjected.html.
- Centers for Medicare & Medicaid Services. (2012). Medicaid program: Eligibility changes under the Affordable Care Act of 2010 (CMS-2349-F). Baltimore, MD: Centers for Medicare & Medicaid Services. Retrieved May 26, 2015, from http://www.medicaid.gov/AffordableCareAct/downloads/CMS-2349-F-RegulatoryImpactAnalysis.pdf.
- Centers for Medicare & Medicaid Services. (2014). Accuracy analysis of the short-term (11-year) national health expenditure projections. Retrieved July 04, 2014, from http://www.cms.gov/NationalHealthExpendData/downloads/ProjectionAccuracy.pdf
- Congressional Budget Office. (2013). Table 1. CBO’s May 2013 Estimate of the Affordable Care Act on Health Insurance Coverage. Washington, D.C.: Congressional Budget Office. Retrieved May 26, 2015, from https://www.cbo.gov/sites/default/files/cbofiles/attachments/43900-2013-05-ACA.pdf.
- Cuckler, G. A., Sisko, A. M., Keehan, S. P., Smith, S. D., Madison, A. J., Poisal, J. A., & Stone, D. A. (2013). National health expenditure projections, 2012–22: slow growth until coverage expands and economy improves. Health Affairs (Millwood), 32(10), 1820–1831. doi:10.1377/hlthaff.2013.0721.CrossRefGoogle Scholar
- Foster, R. (2010). Estimated financial effects of the “Patient Protection and Affordable Care Act”, as amended. Baltimore, MD: Centers for Medicare & Medicaid Services. Retrieved Apr 22, 2010, from http://www.cms.gov/Research-Statistics-Data-and-Systems/Research/ActuarialStudies/Downloads/PPACA_2010-04-22.pdf.
- Goplerud, E., & Center, National Opinion Research. (2013). Consistency of large employer and group health plan benefits with requirements of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Chicago: University of Chicago.Google Scholar
- Levit, K. R., Mark, T. L., Coffey, R. M., Frankel, S., Santora, P., Vandivort-Warren, R., & Malone, K. (2013). Federal spending on behavioral health accelerated during recession as individuals lost employer insurance. Health Affairs, 32(5), 952–962. doi:10.1377/hlthaff.2012.1065.CrossRefPubMedGoogle Scholar
- Mark, T. L., Levit, K. R., Yee, T., & Chow, C. M. (2014). Spending on mental and substance use disorders projected to grow more slowly than all health spending through 2020. Health Affairs (Millwood), 33(8), 1407–1415. doi:10.1377/hlthaff.2014.0163. Research Support, U.S. Gov’t, P.H.S..CrossRefGoogle Scholar
- Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012). Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Molecular Psychiatry, 17(12), 1206–1227. doi:10.1038/mp.2012.47.CrossRefPubMedGoogle Scholar
- Substance Abuse and Mental Health Services Administration. (2012). Results from the 2011 national survey on drug use and health: Mental health findings. Rockville, MD: Substance Abuse and Mental Health Services Administration. HHS Publication No. (SMA) 12-4725.Google Scholar
- Substance Abuse and Mental Health Services Administration. (2013). National expenditures for mental health services and substance abuse treatment, 1986–2009. Rockville, MD: SAMHSA.Google Scholar
- Substance Abuse and Mental Health Services Administration. (2014). Projections of national expenditures for treatment of mental and substance use disorders, 2010–2020. Rockville, MD: Substance Abuse and Mental Health Services Administration.Google Scholar
- Thomas, C., Hodgkin, D., Wallack, S., Martin, T., Ritter, G., & Mark, T. (2007). Mental health and substance abuse treatment prescription drugs: Lessons from a period of high spending growth. Journal of Pharmaceutical Finance Economics and Policy, 16(3), 67.Google Scholar
- U.S. Census Bureau. (2011). Downloadable files containing information from the 2011 American Community Survey. Washington, D.C.: U.S. Census Bureau. Retrieved May 26, 2015, from http://www.census.gov/acs/www/data_documentation/2011_release/.